Abstract
Fractalkine/CX3CL1 is a neuron-associated chemokine, which modulates microglia-induced neurotoxicity activating the specific and unique receptor CX3CR1. CX3CL1/CX3CR1 interaction modulates the release of cytokines from microglia, reducing the level of tumor necrosis factor-α, interleukin-1-β, and nitric oxide and induces the production of neurotrophic substances, both in vivo and in vitro. We have recently shown that blocking adenosine A1 receptors (A1R) with the specific antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) abolishes CX3CL1-mediated rescue of neuronal excitotoxic death and that CX3CL1 induces the release of adenosine from microglia. In this study, we show that the presence of extracellular adenosine is mandatory for the neurotrophic effect of CX3CL1 as reducing adenosine levels in hippocampal cultures, by adenosine deaminase treatment, strongly impairs CX3CL1-mediated neuroprotection. Furthermore, we confirm the predominant role of microglia in mediating the neuronal effects of CX3CL1, because the selective depletion of microglia from hippocampal cultures treated with clodronate-filled liposomes causes the complete loss of effect of CX3CL1. We also show that hippocampal neurons obtained from A1R−/− mice are not protected by CX3CL1 whereas A2AR−/− neurons are. The requirement of functional A1R for neuroprotection is not unique for CX3CL1 as A1R−/− hippocampal neurons are not rescued from Glu-induced cell death by other neurotrophins such as brain-derived neurotrophic factor and erythropoietin, which are fully active on wt neurons.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Agnati LF, Ferrè S, Lluis C, Franco R, Fuxe K (2003). Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55: 509–550.
Biber K, Pinto-Duarte A, Wittendorp MC, Dolga AM, Fernandes CC, Von Frijtag Drabbe Künzel J et al (2008). Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacol 33: 2237–2250.
Boison D (2006). Adenosine kinase, epilepsy and stroke: mechanisms and therapies. Trends Pharmacol Sci 27: 652–658.
Burnstock G (2007). Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87: 659–797.
Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM et al (2006). Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917–924.
Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ (2000). Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20: RC87.
Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y (2006). Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res 84: 1848–1855.
Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D et al (1999). A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192–9200.
Ciccarelli R, Di Iorio P, Bruno V, Battaglia G, D’Alimonte I, D’Onofrio M et al (1999). Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27: 275–281.
Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueňo J, Canals M et al (2008). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1–A2A receptor heteromers. J Neurosci 26: 2080–2087.
Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F et al (2007). Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 104: 10655–10660.
Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM et al (2001). Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 21: 3159–3165.
Cunha RA (2005). Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1: 111–134.
Cunha RA, Vizi ES, Ribeiro JA, Sebastião AM (1996). Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. J Neurochem 67: 2180–2187.
Cunha-Reis D, Fontinha BM, Ribeiro JA, Sebastião AM (2007). Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus. Neuropharmacol 52: 313–320.
de Mendonça A, Sebastião AM, Ribeiro JA (2000). Adenosine: does it have a neuroprotective role after all? Brain Res Brain Res Rev 33: 258–274.
Dénes A, Ferenczi S, Halász J, Környei Z, Kovács K (2008). Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 28: 1707–1721.
Diógenes MJ, Assaife-Lopes N, Pinto-Duarte A, Ribeiro JA, Sebastião AM (2007). Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus 17: 577–585.
Diógenes MJ, Fernandes CC, Sebastião AM, Ribeiro JA (2004). Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24: 2905–2913.
Dolphin AC, Archer ER (1983). An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. Neurosci Lett 43: 49–54.
Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, Bauer M et al (2003). Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol 138: 144–155.
Färber K, Markworth S, Pannasch U, Nolte C, Prinz V, Kronenberg G et al (2008). The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia 56: 331–341.
Fedorova IM, Jacobson MA, Basile A, Jacobson KA (2003). Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol 23: 431–447.
Flajolet M, Wang Z, Futter M, Shen W, Nuangchamnong N, Bendor I et al (2008). FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity. Nat Neurosci 11: 1402–1409.
Fredholm BB (2007). Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Diff 14: 1315–1323.
Fredholm BB, Chen JF, Masino SA, Vaugeois JM (2005). Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45: 385–412.
Gerwins P, Fredholm BB (1992). ATP and its metabolite adenosine act synergisticlly to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line. J Biol Chem 267: 16081–16087.
Gomes CA, Simões PF, Canas PM, Quiroz C, Sebastião AM, Ferré S et al (2009). GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A receptors. J Neurochem 108: 1208–1219.
Heurteaux C, Lauritzen I, Widmann C, Lazdunski M (1995). Essential role of adenosine, adenosine A1 receptors and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 92: 4666–4670.
Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP et al (2006). The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20: 896–905.
Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002). Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37: 314–327.
Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K et al (2003). The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102: 1186–1195.
Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L et al (2001). Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98: 9407–9412.
Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A et al (2000). Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20: 4106–4114.
Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW (2003). CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 137: 210–217.
Lauro C, Di Angelantonio S, Cipriani R, Sobrero F, Antonilli L, Brusadin V et al (2008). Activity of adenosine receptors type 1 is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J Immunol 180: 7590–7596.
Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S et al (2005). Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 166: 19–28.
Lloyd HG, Lindström K, Fredholm BB (1993). Intracellular formation and release of adenosine from rat hippocampal slices evoked by electrical stimulation or energy depletion. Neurochem Int 23: 173–185.
Lyons A, Lynch AM, Downer EJ, Hanley R, O’Sullivan JB, Smith A et al (2009). Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attenuates microglial activation in vivo and in vitro. J Neurochem 110: 1547–1556.
Manzoni OJ, Manabe T, Nicoll RA (1994). Release of adenosine by activation of NMDA receptors in the hippocampus. Science 265: 2098–2101.
Martín ED, Fernández M, Perea G, Pascual O, Haydon PG, Araque A et al (2007). Adenosine released by astrocytes contributes to hypoxia-induced modulation of synaptic transmission. Glia 55: 36–45.
Marín-Teva JL, Dusart I, Colin C, Gervais A, van Rooijen N, Mallat M (2004). Microglia promote the death of developing Purkinje cells. Neuron 41: 535–547.
Michel PP, Marien M, Ruberg M, Colpaert F, Agid Y (1999). Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J Neurochem 72: 2074–2082.
Mizuno T, Kawanokuchi J, Numata K, Suzumura A (2003). Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979: 65–70.
Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo JA et al (1997). Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387: 611–617.
Parkinson FE, Xiong W, Zamzow CR (2005). Astrocytes and neurons: different roles in regulating adenosine levels. Neurol Res 27: 153–160.
Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul J-Y et al (2005). Astrocytic purinergic signaling coordinates synaptic networks. Science 310: 113–116.
Pearson T, Damian K, Lynas RE, Frenguelli BG (2006). Sustained elevation of extracellular adenosine and activation of A(1) receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem 97: 1357–1368.
Pugliese AM, Coppi E, Volpini R, Cristalli G, Corradetti R, Jeong LS et al (2007). Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. Biochem Pharmacol 74: 768–779.
Sawynok J, Liu XJ (2003). Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 69: 313–340.
Schwaninger M, Neher M, Viegas E, Schneider A, Spranger M (1997). Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 69: 1145–1150.
Sebastião AM, Macedo MP, Ribeiro JA (2000). Tonic activation of A(2A) adenosine receptors unmasks, and of A(1( receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. Br J Pharmacol 129: 374–380.
Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T et al (2009). NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiol Aging. E-pub ahead of print.
Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR et al (2002). Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 125: 59–65.
Sunnemark D, Eltayeb S, Nilsson M, Wallström E, Lassmann H, Olsson T et al (2005). CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation 2: 17–31.
Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M et al (2008). Adenosine A2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem 104: 279–286.
Tran PB, Miller RJ (2003). Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci 4: 444–455.
van Rooijen N, Sanders A (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83–93.
van Rooijen N, Sanders A, van den Berg TK (1996). Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 193: 93–99.
Wittendorp MC, Boddeke HWGM, Biber K (2004). Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46: 410–418.
Zimmermann H (1996). Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog Neurobiol 49: 589–618.
Zujovic V, Benavides J, Vigé X, Carter C, Taupin V (2000). Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305–315.
Zujovic V, Schussler N, Jourdain D, Duverger D, Taupin V (2001). In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-isoprostane production induced by intracerebroventricular injection of LPS. J Neuroimmunol 115: 135–143.
Acknowledgements
This work was granted by Ministero Università & Ricerca scientifica (PRIN to CL), by Fondazione Cenci Bolognetti (to CL), by Ministero Salute (Ricerca finalizzata to CL and FE), and by Swedish Science Research Council (to BBF). We thank Dr Knut Biber for discussion.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Rights and permissions
About this article
Cite this article
Lauro, C., Cipriani, R., Catalano, M. et al. Adenosine A1 Receptors and Microglial Cells Mediate CX3CL1-Induced Protection of Hippocampal Neurons Against Glu-Induced Death. Neuropsychopharmacol 35, 1550–1559 (2010). https://doi.org/10.1038/npp.2010.26
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2010.26
Keywords
This article is cited by
-
Implications of fractalkine on glial function, ablation and glial proteins/receptors/markers—understanding its therapeutic usefulness in neurological settings: a narrative review
Future Journal of Pharmaceutical Sciences (2022)
-
Cellular, synaptic, and network effects of chemokines in the central nervous system and their implications to behavior
Pharmacological Reports (2021)
-
Protective effects of CX3CR1 on autoimmune inflammation in a chronic EAE model for MS through modulation of antigen-presenting cell-related molecular MHC-II and its regulators
Neurological Sciences (2019)
-
Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma
Scientific Reports (2018)
-
Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents
Molecular Neurobiology (2017)
